ArticleInflammation2025
RUNX1 Induces Central Neuropathic Pain by Activating Microglia and Triggering the Inflammatory Response in Spinal Cord Injury.
Article in Inflammation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cell-type specific impact of opioid use disorder and HIV on the human forebrain and cerebellum.bioRxiv : the preprint server for biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Runt-related transcription factor 1 (RUNX1) is a highly conserved transcription factor involved in immune regulation, inflammation, and nociceptive neuron differentiation. However, its role in central neuropathic pain (CNP) induced by SCI remains unclear. Here, we investigated RUNX1 expression after SCI and its impact on CNP. Using scAAV-mediated RUNX1 knockdown in the spinal cord of SCI rats, we assessed nociceptive behaviors of mechanical allodynia and thermal hyperalgesia by hind paw withdrawal threshold (PWT) and paw withdrawal latency (PWL) before injury and at 21-, 35-, and 49-days post-injury. RUNX1 mRNA and protein levels were analyzed via RT-qPCR and Western blotting, while immunohistochemistry was used to examine its distribution. Our findings revealed that RUNX1 expression was significantly elevated in microglia following SCI. RUNX1 knockdown notably increased PWT and PWL as well as a significant decrease in the aberrant sprouting of nociceptive fibers in SCI rats. Furthermore, in lipopolysaccharide (LPS)-treated BV-2 microglia, RUNX1 knockdown markedly reduced microglial activation and inflammation. A similar reduction in microglial activation and neuroinflammation was observed in SCI rats following RUNX1 knockdown. These findings suggest that RUNX1 contributes to CNP after SCI by promoting microglial activation and neuroinflammation, identifying it as a potential therapeutic target for SCI-induced neuropathic pain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.